First-in-human intracochlear application of human stromal cell-derived extracellular vesicles.

Autor: Warnecke A; Department of Otorhinolaryngology, Head and Neck Surgery Hannover Medical School Hannover Germany., Prenzler N; Department of Otorhinolaryngology, Head and Neck Surgery Hannover Medical School Hannover Germany., Harre J; Department of Otorhinolaryngology, Head and Neck Surgery Hannover Medical School Hannover Germany., Köhl U; Institute for Cellular Therapeutics Hannover and Institute of Clinical Immunology Hannover Medical School University of Leipzig as well as Fraunhofer Institute for Cell Therapy and Immunology (IZI) Leipzig Germany., Gärtner L; Department of Otorhinolaryngology, Head and Neck Surgery Hannover Medical School Hannover Germany., Lenarz T; Department of Otorhinolaryngology, Head and Neck Surgery Hannover Medical School Hannover Germany., Laner-Plamberger S; Department of Transfusion Medicine University Hospital Salzburger Landeskliniken GesmbH (SALK) and Paracelsus Medical University (PMU) Salzburg Austria., Wietzorrek G; Institute of Molecular and Cellular Pharmacology Medical University of Innsbruck Innsbruck Austria., Staecker H; Department of Otolaryngology Head and Neck Surgery University of Kansas School of Medicine Kansas City Kansas USA., Lassacher T; GMP Unit Spinal Cord Injury & Tissue Regeneration Centre Salzburg (SCI-TReCS) Paracelsus Medical University (PMU) Salzburg Austria.; Research Program Nanovesicular Therapeutics Paracelsus Medical University (PMU) Salzburg Austria., Hollerweger J; GMP Unit Spinal Cord Injury & Tissue Regeneration Centre Salzburg (SCI-TReCS) Paracelsus Medical University (PMU) Salzburg Austria.; Research Program Nanovesicular Therapeutics Paracelsus Medical University (PMU) Salzburg Austria., Gimona M; Department of Transfusion Medicine University Hospital Salzburger Landeskliniken GesmbH (SALK) and Paracelsus Medical University (PMU) Salzburg Austria.; GMP Unit Spinal Cord Injury & Tissue Regeneration Centre Salzburg (SCI-TReCS) Paracelsus Medical University (PMU) Salzburg Austria.; Research Program Nanovesicular Therapeutics Paracelsus Medical University (PMU) Salzburg Austria.; Research and Transfer Centre for Extracellular Vesicle Theralytic Technologies Salzburg Austria., Rohde E; Department of Transfusion Medicine University Hospital Salzburger Landeskliniken GesmbH (SALK) and Paracelsus Medical University (PMU) Salzburg Austria.; GMP Unit Spinal Cord Injury & Tissue Regeneration Centre Salzburg (SCI-TReCS) Paracelsus Medical University (PMU) Salzburg Austria.; Research and Transfer Centre for Extracellular Vesicle Theralytic Technologies Salzburg Austria.
Jazyk: angličtina
Zdroj: Journal of extracellular vesicles [J Extracell Vesicles] 2021 Jun; Vol. 10 (8), pp. e12094. Date of Electronic Publication: 2021 Jun 04.
DOI: 10.1002/jev2.12094
Abstrakt: Extracellular vesicles (EVs) derived from the secretome of human mesenchymal stromal cells (MSC) contain numerous factors that are known to exert anti-inflammatory effects. MSC-EVs may serve as promising cell-based therapeutics for the inner ear to attenuate inflammation-based side effects from cochlear implantation which represents an unmet clinical need. In an individual treatment performed on a 'named patient basis', we intraoperatively applied allogeneic umbilical cord-derived MSC-EVs (UC-MSC-EVs) produced according to good manufacturing practice. A 55-year-old patient suffering from Menière's disease was treated with intracochlear delivery of EVs prior to the insertion of a cochlear implant. This first-in-human use of UC-MSC-EVs demonstrates the feasibility of this novel adjuvant therapeutic approach. The safety and efficacy of intracochlear EV-application to attenuate side effects of cochlea implants have to be determined in controlled clinical trials.
(© 2021 The Authors. Journal of Extracellular Vesicles published by Wiley Periodicals, LLC on behalf of the International Society for Extracellular Vesicles.)
Databáze: MEDLINE
Externí odkaz: